Table 3.
Immunotherapy trials for patients with localized esophageal squamous cell carcinoma in perioperative settings.
| National Clinical Trial Number | Phase | N | Immunotherapeutic Agent | Strategy Experimental Arm | Strategy Control Arm | Ethnicity | Primary Endpoint |
|---|---|---|---|---|---|---|---|
| NCT04807673 | III | 342 | Pembrolizumab (P) | P + CHT + OP + P | CRT + OP | Asian | EFS |
| NCT05244798 | III | 360 | Tislelizumab (T) | T + CRT + OP | T + CHT + OP | Asian | pCR |
| NCT04280822 | III | 400 | Toripalimab (To) | To + CHT + OP + To | CHT + OP | Asian | EFS |
| NCT04973306 | II/III | 176 | Tislelizumab (T) | T + CROSS + OP | CROSS + OP | Asian | pCR |
| NCT05213312 | II/III | 90 | Nivolumab (N) | N + CHT + OP + (ad N for non-pCR) | CHT + OP + (ad N for non-pCR) | Asian | pCR |
| NCT05357846 | III | 422 | Sintilimab (S) | S + CRT + OP | CRT + OP | Asian | OS |
Abbreviations: N = number of patients; CHT = chemotherapy; CRT = chemoradiotherapy; OP = surgery; pCR = pathological complete remission; OS = overall survival, EFS = event-free survival.